MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
A phase 3 trial of Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide in follicular lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.
Overview
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma is a phase 3 interventional study registered as NCT04834024 by Beijing Mabworks Biotech Co., Ltd., with 168 participants planned, started 2021-06-02 and due to reach its primary completion in 2025-03. Interventions recorded: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide and lenalinomide.
Similar pages
not linked directly; found by shared links- TrialA Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Shares Beijing Mabworks Biotech and the tag pipeline.
- TrialA Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Shares Beijing Mabworks Biotech and the tag pipeline.
- TrialMIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
- TrialPhase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Shares Follicular lymphoma and the tag pipeline.
- TrialDose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Shares Follicular lymphoma and the tag pipeline.
- TrialGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Shares Follicular lymphoma and the tag pipeline.
- TreatmentTC011
Shares Follicular lymphoma and the tag pipeline.
- TreatmentCRC01
Shares Follicular lymphoma and the tag pipeline.